194 related articles for article (PubMed ID: 38456406)
41. Heart failure with preserved ejection fraction and atrial fibrillation: recent advances and open questions.
Fauchier L; Bisson A; Bodin A
BMC Med; 2023 Feb; 21(1):54. PubMed ID: 36782248
[TBL] [Abstract][Full Text] [Related]
42. Effect of the angiotensin-receptor-neprilysin inhibitor in heart failure patients with left ventricular ejection fraction higher than 40.
Zhao M; Xin Y; Li J; Cao X; Liu X
Medicine (Baltimore); 2019 Sep; 98(39):e17296. PubMed ID: 31574852
[TBL] [Abstract][Full Text] [Related]
43. Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction.
Clemmer JS; Ward TJ; Lirette ST
ESC Heart Fail; 2023 Jun; 10(3):2010-2018. PubMed ID: 37042079
[TBL] [Abstract][Full Text] [Related]
44. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors among patients with heart failure with preserved ejection fraction.
Riaz M; Smith SM; Dietrich EA; Winchester DE; Guo J; Park H
Pharmacotherapy; 2023 Oct; 43(10):1024-1031. PubMed ID: 37459069
[TBL] [Abstract][Full Text] [Related]
45. Association Between Use of Sodium-Glucose Cotransporter-2 Inhibitors or Angiotensin Receptor-Neprilysin Inhibitor and the Risk of Atherosclerotic Cardiovascular Disease With Coexisting Diabetes and Heart Failure.
Lin YW; Lin CH; Lin CL; Lin CH; Lin MH
J Cardiovasc Pharmacol Ther; 2024; 29():10742484241233872. PubMed ID: 38438119
[TBL] [Abstract][Full Text] [Related]
46. Heart failure progression and mortality in atrial fibrillation patients with preserved or reduced left ventricular ejection fraction.
Slee A; Saad M; Saksena S
J Interv Card Electrophysiol; 2019 Sep; 55(3):325-331. PubMed ID: 30887281
[TBL] [Abstract][Full Text] [Related]
47. Impact of atrial fibrillation in patients with heart failure and reduced, mid-range or preserved ejection fraction.
Son MK; Park JJ; Lim NK; Kim WH; Choi DJ
Heart; 2020 Aug; 106(15):1160-1168. PubMed ID: 32341140
[TBL] [Abstract][Full Text] [Related]
48. Long-term impact of angiotensin receptor-neprilysin inhibitor based on short-term treatment response in heart failure.
Park HK; Park JS; Kim MS; Lee E; Choi H; Park YJ; Park BE; Kim HN; Kim N; Bae MH; Lee JH; Park HS; Cho Y; Jang SY; Yang DH
ESC Heart Fail; 2023 Dec; 10(6):3430-3437. PubMed ID: 37705397
[TBL] [Abstract][Full Text] [Related]
49. A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction.
Tromp J; Ouwerkerk W; van Veldhuisen DJ; Hillege HL; Richards AM; van der Meer P; Anand IS; Lam CSP; Voors AA
JACC Heart Fail; 2022 Feb; 10(2):73-84. PubMed ID: 34895860
[TBL] [Abstract][Full Text] [Related]
50. Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry.
Zafrir B; Lund LH; Laroche C; Ruschitzka F; Crespo-Leiro MG; Coats AJS; Anker SD; Filippatos G; Seferovic PM; Maggioni AP; De Mora Martin M; Polonski L; Silva-Cardoso J; Amir O;
Eur Heart J; 2018 Dec; 39(48):4277-4284. PubMed ID: 30325423
[TBL] [Abstract][Full Text] [Related]
51. Heart Failure with Preserved Ejection Fraction: Management Guidelines (From Heart Failure Association of India, Endorsed by Association of Physicians of India).
S H; Oomman A; Jadhav UM; Raghuraman B; Mohanan PP; Tiwaskar M; Wander GS; Chopra VK
J Assoc Physicians India; 2022 Aug; 70(8):11-12. PubMed ID: 36082729
[TBL] [Abstract][Full Text] [Related]
52. Risks of Heart Failure, Stroke, and Bleeding in Atrial Fibrillation According to Heart Failure Phenotypes.
Inciardi RM; Giugliano RP; Park JG; Nordio F; Ruff CT; Chen C; Lanz HJ; Antman EM; Braunwald E; Solomon SD
JACC Clin Electrophysiol; 2023 Apr; 9(4):569-580. PubMed ID: 37100536
[TBL] [Abstract][Full Text] [Related]
53. Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis.
Zhang N; Wang Y; Tse G; Korantzopoulos P; Letsas KP; Zhang Q; Li G; Lip GYH; Liu T
Eur J Prev Cardiol; 2022 Feb; 28(17):1961-1973. PubMed ID: 34792124
[TBL] [Abstract][Full Text] [Related]
54. Effects of different sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a network meta-analysis.
Lan X; Zhu H; Cao Y; Hu Y; Fan X; Zhang K; Wu M
Front Cardiovasc Med; 2024; 11():1379765. PubMed ID: 38845687
[TBL] [Abstract][Full Text] [Related]
55. Safety and Efficacy of the Combination of Sacubitril/Valsartan and SGLT2i in HFrEF Patients (SECSI Registry).
Jiménez-Blanco Bravo M; Valle A; Gayán Ordás J; Del Prado Díaz S; Cordero Pereda D; Morillas Climent H; Bascompte Claret R; Seller Moya J; Zamorano Gómez JL; Alonso Salinas GL
J Cardiovasc Pharmacol; 2021 Nov; 78(5):e662-e668. PubMed ID: 34321396
[TBL] [Abstract][Full Text] [Related]
56. Drugs That Ameliorate Epicardial Adipose Tissue Inflammation May Have Discordant Effects in Heart Failure With a Preserved Ejection Fraction as Compared With a Reduced Ejection Fraction.
Packer M
J Card Fail; 2019 Dec; 25(12):986-1003. PubMed ID: 31541742
[TBL] [Abstract][Full Text] [Related]
57. Association between sodium-glucose cotransporter-2 inhibitors and arrhythmic outcomes in patients with diabetes and pre-existing atrial fibrillation.
Fichadiya A; Quinn A; Au F; Campbell D; Lau D; Ronksley P; Beall R; Campbell DJT; Wilton SB; Chew DS
Europace; 2024 Mar; 26(3):. PubMed ID: 38484180
[TBL] [Abstract][Full Text] [Related]
58. Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
Chandra A; Vaduganathan M; Lewis EF; Claggett BL; Rizkala AR; Wang W; Lefkowitz MP; Shi VC; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; McMurray JJV; Solomon SD;
JACC Heart Fail; 2019 Oct; 7(10):862-874. PubMed ID: 31302043
[TBL] [Abstract][Full Text] [Related]
59. Left atrial volume and left ventricular mass indices in heart failure with preserved and reduced ejection fraction.
Gehlken C; Screever EM; Suthahar N; van der Meer P; Westenbrink BD; Coster JE; Van Veldhuisen DJ; de Boer RA; Meijers WC
ESC Heart Fail; 2021 Aug; 8(4):2458-2466. PubMed ID: 34085774
[TBL] [Abstract][Full Text] [Related]
60. Frailty and uptake of angiotensin receptor neprilysin inhibitor for heart failure with reduced ejection fraction.
Lee YC; Lin JK; Ko D; Cheng S; Patorno E; Glynn RJ; Tsacogianis T; Kim DH
J Am Geriatr Soc; 2023 Oct; 71(10):3110-3121. PubMed ID: 37345734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]